Big-spending investors have been ripping Genmab shares of the shelves in the beginning of the year and last week the share went up by another 12 % in one day, following to positive announcements from the company:
The candidate drug Daratumumab gained the coveted Breakthrough Therapy designation from the FDA and the already marketed drug Arzerra performed well in a new combination study.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app